Endometrial sampling is taken one cycle before planned embryo transferring. Your Hormone Replacement Therapy (HRT) scheme should be the same as it will be in the month of your IVF embryo transfer. The sample should be taken on the day when your day 5 embryo transfer should take place in the following month.

It is like a simulation for gaining confidence and finding out the perfect timing for your embryo transfer.

Your doctor is responsible for informing you about the benefits and outcome of the test and making the necessary changes in your treatment plan. You will sign the Patient Informed Consent Form before your sample is taken.

The analysis begins once the sample has arrived to the laboratory. The testing is based on gene expression biomarker profiling, which reflects the readiness of the endometrium. RNA material is extracted from the tissue sample and 67 informative biomarker genes are analysed.

The beREADY test results are sent to your doctor within 14 business days after receiving the sample. The report shows your endometrium’s receptivity level and indicates if any changes are needed in your IVF plan.

Based on the results of your test, the necessary changes could be applied in your next IVF cycle(s). If beREADY report shows that your WOI is significantly shifted and re-sampling is recommended, the analysis of the second sample is free-of-charge. The re-sampling is highly recommended to make sure that the receptiveness of endometrium is achieved with adjustments. It gives you the confidence of knowing that your embryo transfer is planned at the most optimal time, which will increase your chance of successful pregnancy.

The beREADY test has been validated under clinical conditions in two independent international IVF clinics to demonstrate the test’s accuracy. In total, 45 HRT patients’ samples were involved in a comparison against the leading endometrial receptivity test on the market. The concordance rate between two tests was 96 percent.

The small difference is due to the difference in testing methods. The beREADY applies a highly accurate TAC-seq DNA sequencing technology that enables us to detect bio-marker molecules at a single molecule level, providing us with the ultimate accuracy.

The beREADY test detects 67 biomarker genes that indicate a receptive endometrium. The genes are detected by patent pending and published TAC-seq methodology that applies advanced Illumina DNA sequencing technology. The applied methodology makes endometrium biomarker profiling extremely accurate, detecting the key molecules at a single-molecule level. Extracted biomarker molecules from your sample are tagged by unique DNA barcode, which makes it possible to count the molecule copies at original level even after laboratory manipulations like sample preparation for analysis. TAC-seq technology detects even the slightest of changes in your sample, revealing all progress of endometrial maturation.